AGAbdullah A. Khan Ghyathuddin

Abdullah A. Khan Ghyathuddin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdullah A. Khan Ghyathuddin has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety and quality evaluation of commercial wheat flour in Saudi Arabia through microbiological, chemical, and molecular analyses: a preliminary baseline assessment

    by Abdullah A. Khan Ghyathuddin, Faisal Al-Sarraj, Atif Bamagoos, Nada M. Nass, Ehab Mattar, Abdullah Baz, Ibrahim Alotibi, Ali Shaibah, Mohammed A. Almatry, Saleh M. Al-Maaqar

    Wheat flour is a global staple food commodity, yet its microbiological and chemical safety remains a public health concern due to potential contamination throughout the production and supply chain. This study provides a preliminary baseline assessment of the quality and safety of 14 commercial wheat flour samples (X1–X14) obtained from markets in Jeddah, Saudi Arabia. Standard microbiological methods were employed to detect pathogenic indicators. Heavy metal concentrations were quantified. Ochratoxin-A and total aflatoxins (B1 + B2 + G1 + G2) were analyzed, while pesticide residues were determined. A total of 23 bacterial isolates were purified and identified via 16S rRNA gene Sanger sequencing, with phylogenetic trees constructed using MEGA12, and hemolytic activity was assessed on sheep blood agar. All samples were negative for Salmonella spp., Staphylococcus aureus ( S. aureus ), Bacillus cereus ( B. cereus ), and Escherichia coli ( E. coli ) were below 10 CFU/g, indicating compliance with international safety standards. However, yeast and mold counts varied significantly, with one sample (X8) exhibiting a critically high count (830 CFU/g). Heavy metal levels were generally within Codex Alimentarius limits, though one sample contained elevated lead (0.566 mg/kg). Ochratoxin-A was detected in Three samples (X1: 0.17 μg/kg; X2: 0.12 μg/kg; X9: 0.14 μg/kg), while total aflatoxins were absent from all samples. The most prevalent pesticide residue was deltamethrin (X2, X3, X4, X6; range 0.015–0.059 mg/kg), followed by chlorpyrifos ethyl (X3: 0.009 mg/kg; X6: 0.008 mg/kg). Molecular identification revealed a taxonomically diverse bacterial community dominated by the genus Staphylococcus ( 13/23 isolates , 56.5% ), followed by Rothia kristinae ( 3/23 ), Bacillus paramycoides ( 2/23 ), Peribacillus frigoritolerans ( 1/23 ), and other genera ( 4/23 ). Hemolytic activity testing revealed that all staphylococcal isolates were gamma-hemolytic (non-hemolytic), whereas the three Bacillus isolates ( Bacillus paramycoides and Peribacillus frigoritolerans ) exhibited beta-hemolysis. These preliminary findings underscore the necessity for routine monitoring of post-harvest handling, storage conditions, and pesticide residues to ensure consumer safety. Due to the limited sample size ( n = 14), future studies with broader geographic and seasonal coverage are recommended.

  • Open Access

    Oncolytic bacteria: A revolutionary approach to cancer therapy

    by Mohsen A. Khormi, Saleh M. Al-Maaqar, Abdulaziz R. Al Johni, Nasser A. Al-Tayyar, Jafar Abdullah Alhamad, Abdullah A. Ghyathuddin, Zakia Alblawi, Sabreen M. Behairy, Mohammed A. Alghamdi, Wael A. Alsubhi, et al.

    Cancer is one of the most devastating diseases all over the globe, and it is the second worldwide cause of death, exceeded only by cardiovascular diseases. The therapeutic approach to human cancer has evolved significantly and has varied depending on the type and stage of cancer, as well as the general health status of the patient. Despite the advancements in cancer treatment, various challenges persist in the treatment of cancer, including side effects, drug resistance, and incomplete eradication of tumors. The use of oncolytic bacteria (cancer targeting and destroying bacteria) has been identified to have several advantages over the traditional methods of cancer treatment. Several bacterial species have been identified to be used in the treatment of different types of cancers. Oncolytic therapy can be achieved through the use of a naturally occurring and/or genetically modified bacterial species, including Clostridium , Salmonella, Escherichia coli, and Listeria spp. with their toxins, enzymes, biofilms, and secondary metabolites as well as their spores that leads to direct or indirect killing of cancer cells. This review provides some highlights about the biology and therapeutic potential of oncolytic bacteria individually or in combination with other therapeutic approaches against different types of cancers. Besides, the current challenges and future perspectives will be explored.